Servier’s decision to exit a Parkinson’s disease pact has triggered belt tightening at French biotech Oncodesign Precision Medicine. | Servier’s decision to exit a Parkinson’s disease pact has ...

As the Department of Health and Human Services grapples with the fallout of mass layoffs directed by Secretary Robert F.

Apollomics has tagged out of its partnership with TYG Oncology, terminating an immuno-oncology pact as part of a push to cut ...

Sangamo Therapeutics has stacked up $18 million cash from Eli Lilly in a licensing deal that will let the pharma use the ...

Neurona Therapeutics has circled up $102 million to push its off-the-shelf cell therapy for epilepsy through phase 3 testing.

Siemens AG—and that’s Siemens Siemens, not Siemens Healthineers—is expanding its industrial software business further into ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. | Roche has reported preliminary ...

The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease, rejecting its second ...

BeiGene is scrapping ociperlimab over a disappointing phase 3 outlook two years after Novartis handed back the anti-TIGIT ...

Boehringer Ingelheim is pumping funds into the still-hot antibody-drug conjugate space, committing 27 million Swiss francs ...

“As part of Cyclacel’s efforts to reduce operating costs, it has determined to focus on the development of plogosertib, a polo-like kinase 1 inhibitor for treatment of advanced cancers and ...

While Pliant Therapeutics and Acelyrin recently blocked ever-eager acquirer Concentra Biosciences with “poison pill” defenses ...